This is a working overview of reconstitution, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-02 and is reviewed periodically as new material appears.
Water is a central factor in peptide degradation because it enables hydrolysis and mobilizes reactive species. Lyophilized or dry powders typically remain stable for longer than solutions when kept cool and dry. Oxygen can drive oxidation, particularly for sulfur-containing residues, while light can catalyze side-chain damage. Buffer choice and pH influence charge state and can accelerate or slow deamidation and aggregation. Freeze-thaw cycles may concentrate solutes or promote ice-induced aggregation, so minimizing such cycles is a common handling goal.
Lyophilization removes water under vacuum from a frozen solution, leaving a porous cake or powder. Formulation excipients such as sugars or polyols can stabilize structure during freezing and drying and can raise the glass transition temperature. Residual moisture in the final product remains a critical variable because even small amounts can support hydrolysis over time. Storage recommendations often specify desiccation, darkness, and low temperature, though exact conditions depend on the peptide and its intended use. Stability studies measure changes under defined conditions rather than predicting absolute shelf life.
Peptides are short chains of amino acids linked by amide bonds. Their stability depends on sequence, length, and the chemical environment. Common degradation routes include hydrolysis of the peptide backbone, oxidation of methionine or cysteine residues, deamidation of asparagine or glutamine, and aggregation through hydrophobic or electrostatic interactions. These processes can alter mass, charge, or biological activity, so storage conditions aim to slow them. The relative importance of each route varies widely among peptides.
Cold-chain shipping uses insulated containers, phase-change packs, and temperature indicators. Dry ice maintains -70 °C or lower but requires venting to avoid pressure buildup. Gel packs provide 2-8 °C for shorter transit. Upon arrival, recipients should record temperature indicators and transfer vials promptly to storage. Deviations from specified conditions should be documented and may require analytical re-check. The effect of a brief temperature excursion is peptide-specific and not always predictable from general rules.
Handling begins with receipt and inspection. Vials should be checked for damage, label integrity, and temperature history. Lyophilized peptides should be allowed to equilibrate to room temperature before opening to prevent condensation. Solutions should be prepared in a clean, calibrated environment using appropriate solvents. Personal protective equipment and containment reduce exposure and contamination. Documentation of lot number, date, and storage location supports traceability. The goal is to limit repeated temperature changes, moisture exposure, and microbial contamination.
Reconstitution solvent depends on peptide solubility and intended use; water, buffer, or small amounts of organic solvent may be needed. After dissolution, solutions are typically aliquoted into single-use portions to avoid repeated freeze-thaw cycles. Aliquots are stored at -20 °C or -80 °C, depending on stability. Labels include concentration, solvent, date, and operator. Sterile filtration may be used when microbial control is required, but filters can adsorb peptides. The optimal concentration and solvent are often determined empirically.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for lyophilized or dry peptide material |
| Solubility class | Often freely soluble in water | Depends on sequence and counterion |
| Typical dry storage temperature | -20 °C or lower | Cooler conditions generally slow degradation |
| Common degradation route | Hydrolysis, oxidation, deamidation | Relative importance varies by sequence |
| Typical analytical method | RP-HPLC and LC-MS | Used to assess purity and mass |
Temperature is a primary variable because most degradation reactions slow as thermal energy decreases. Lyophilized powders are commonly held at -20 °C for routine work and at -80 °C for longer archival periods, though exact recommendations depend on the peptide. Solutions are less stable than dry powders in many cases, and repeated freeze-thaw cycles can promote aggregation or precipitation. Inert atmospheres, such as argon or nitrogen, can limit oxidation for oxygen-sensitive sequences. Desiccants reduce water activity, which lowers hydrolysis rates during storage.
Light exposure can damage aromatic residues and certain labels, so amber vials or opaque containers are often used. pH control matters in solution, as extreme acidity or alkalinity accelerates backbone cleavage; buffers may also introduce ions that affect solubility. Microbial growth is a concern for aqueous preparations that lack preservatives, though many research peptides are handled in sterile or low-bioburden conditions. Container materials can adsorb peptides, particularly hydrophobic or positively charged sequences, reducing recovery. These factors interact, meaning storage decisions balance chemical stability, physical state, and intended use.
After reconstitution, solutions are divided into single-use aliquots and stored at -80°C. Labels include peptide name, concentration, buffer composition, date, and lot number. Freeze-thaw cycles are minimized by thawing only the needed aliquot on ice or at room temperature. Some peptides benefit from the addition of a carrier protein, such as bovine serum albumin, or a cryoprotectant like glycerol to reduce adsorption to plastic. Glass vials with low-binding surfaces are preferred for dilute solutions. Shipping of frozen aliquots uses dry ice and insulated containers to maintain the cold chain.
Receiving a peptide shipment requires immediate inspection of the packaging and temperature indicators. Any deviation from the specified cold chain should be documented and investigated. Upon arrival, solid peptides are generally kept at -20°C, whereas liquid formulations are stored at -80°C. Vials should be kept upright and protected from light. Repeated warming and cooling of the entire container is avoided by preparing smaller working aliquots. A log of lot numbers, receipt dates, and storage locations supports traceability and quality control.
After reconstitution, dividing the solution into single-use aliquots limits multiple warming and cooling events and reduces contamination risk. Low-binding polypropylene tubes are often preferred because peptides can adsorb to glass or untreated plastic surfaces. Filling headspace with nitrogen or argon can slow oxidation, and amber or foil-wrapped containers reduce photodegradation. Each aliquot should be labeled with peptide identity, concentration, date, and storage conditions. Frozen aliquots should be thawed quickly and kept on ice until use.
When a peptide arrives, the vial should be inspected for damage, and its label, lot number, and accompanying analytical data should be recorded. Cold vials should equilibrate to room temperature before opening to prevent condensation on the powder. Moisture uptake can reduce stability and complicate accurate weighing or reconstitution. Inventory systems that track date, quantity, and storage location help prevent unnecessary temperature cycling. Personnel should follow institutional or manufacturer instructions for any specific peptide.
=== Psychotrope Wirkung === Es ist bekannt, dass Strukturanaloga des HHC an den Cannabinoid-Rezeptor 1 (CB1) binden und psychotrope Effekte erzeugen, wobei 9β-HHC eine erheblich stärkere Wirkung zeigt als 9α-HHC. Nasrallah und Garg (2023) untersuchten 9β-HHC und 9α-HHC und deren Wechselwirkungen mit CB1- und CB2-Rezeptoren. Sie untersuchten sowohl die Bindungsaffinität dieser Verbindungen, also wie gut sie an die Rezeptoren andocken können, als auch ihre funktionale Aktivität, d. h., wie effektiv sie diese Rezeptoren aktivieren. Die Studie ergab, dass 9β-HHC in Bezug auf die Bindung und Aktivierung der Rezeptoren ähnlich wirksam ist wie Δ9-THC. Im Gegensatz dazu zeigte 9α-HHC eine deutlich geringere Wirksamkeit – etwa zehnmal schwächer sowohl in der Bindungsaffinität als auch in der funktionalen Aktivität.
=== Toxikologische Bewertung === Das Bundesinstitut für Risikobewertung (BfR) bewertet die wissenschaftliche Datenlage zu HHC als unvollständig. Es gibt Erkenntnisse aus Tier- und Zellkulturstudien, Hinweise aus Erfahrungsberichten von Personen, die HHC konsumieren, sowie Fallberichte. Sie deuten darauf hin, dass HHC insbesondere in seiner ß-HHC-Form ähnliche Wirkungen auslösen kann wie Δ9-THC, auch wenn dafür wahrscheinlich etwas höhere Dosen nötig sind. Die Wahrscheinlichkeit gesundheitlicher Beeinträchtigungen bei einem illegalen oder versehentlichen Konsum von HHC für die Allgemeinbevölkerung bewertet das BfR als hoch. Die HHC-Gehalte in Produkten, die irrtümlich als Lebensmittel wahrgenommen werden können, wie etwa in Weingummi-artigen Erzeugnissen mit 25 Milligramm HHC pro Stück – können nach derzeitigem Kenntnisstand dazu führen, bei konsumierenden Personen einen Rauschzustand auszulösen. Aktuelle Kenntnisse zeigen, dass durch die Aufnahme größerer Mengen schwerwiegende Vergiftungen auftreten können.
=== Deutschland === Zum 23. Mai 2026 wurde HHC durch die Siebenundzwanzigste Verordnung zur Änderung von Anlagen des Betäubungsmittelgesetzes (27. BtMGAnlÄndV) als verkehrsfähiges, aber nicht verschreibungsfähiges Betäubungsmittel eingestuft. Damit sind auch Erwerb und Besitz strafbar. Eine Ausnahme besteht, wenn es sich um Cannabis zu medizinischen Zwecken oder zu medizinisch-wissenschaftlichen Zwecken im Sinne des Medizinal-Cannabisgesetzes handelt oder wenn es sich um eine nichtsynthetische Form von HHC handelt, die zu nichtmedizinischen Zwecken im Verkehr ist. Zuvor waren im Juni 2024 die Herstellung und der Vertrieb von HHC durch die Fünfte Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes (NpSG) verboten worden. Besitz und Erwerb für den Eigenbedarf waren nicht unter Strafe gestellt. Die Verordnung wurde am 26. Juni 2024 im Bundesgesetzblatt veröffentlicht. Zubereitungen mit synthetischem HHC wurden seit 2022 in Form von Vape-Liquids und -Kartuschen, Ölen, Blüten und Lebensmitteln („Edibles“) vertrieben. Bei den Blüten handelte es sich um getrockneten THC-armen Nutzhanf, der mit HHC versetzt wurde.
=== Österreich === In Österreich fällt Hexahydrocannabinol als Extrakt aus der Cannabispflanze unter das Suchtmittelgesetz und ist damit illegal. Synthetisch aus THC oder CBD hergestelltes HHC war bis zum 22. März 2023 legal. Seit dem 23. März 2023 fällt es unter die „Verordnung über Neue Psychoaktive Substanzen“ und die Herstellung sowie der Handel sind verboten. Besitz und Konsum bleiben weiterhin legal.
Sources: de.wikipedia.org
Peptide degradation can arise from hydrolysis, oxidation, deamidation, and aggregation. The dominant route depends on the peptide sequence and the storage environment. Temperature, moisture, oxygen, light, and pH all influence the rate.
Freezing slows many chemical reactions but does not stop all degradation. Repeated freeze-thaw cycles can promote aggregation or precipitation. Dry powders and solutions may respond differently to freezing.
pH affects the charge state of ionizable groups and can influence deamidation, hydrolysis, and aggregation. A pH that stabilizes one peptide may destabilize another. Buffer components can also participate in degradation or stabilization.
No. Allowing the sealed vial to equilibrate to room temperature reduces condensation on the powder. Condensation can introduce moisture and promote degradation. Equilibration usually takes 15 to 30 minutes depending on vial size.